Brief: Bio-Path Holdings Announces First Patient Dosed In Phase 1/1B Study Of Bp1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
24/10/2022 13:51
Oct 24 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1/1B
STUDY OF BP1002 IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA
PATIENTS
Source text for Eikon: ID:nGNX1tBX6D
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia